Cervical cancer screening and treatment using self-collected HPV testing in Mozambique
Official title: A hybrid type III effectiveness-implementation, pragmatic intervention trial for cervical cancer screen and treat in Mozambique
Funded at Tulane University of Louisiana · NIH-11535299 · Data updated 2026-11-12
This grant tests a practical way to screen and treat cervical cancer in Mozambique by letting women collect their own samples for HPV tests and then receive treatment as needed.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $202,994 |
| NIH project number | 3U01CA294674-03S1 |
| Project ID | NIH-11535299 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women aged 25-49 in Mozambique who are eligible for HPV-based screening and treatment programs.
✕Less likely to help
Women outside the screening age range or in settings without HPV testing capacity may not benefit.
What this research studies
This project will implement a self-collection HPV testing approach for cervical cancer screening in Mozambique and pair it with an effective treatment pathway. It combines patient-centered screening with real-world application to see how well the approach works in routine care settings. The study uses a hybrid type III design to measure both how well the program works in practice and how best to implement it in health facilities. Results will inform scalable strategies to reduce cervical cancer deaths in LMICs.
Why it matters
Potential benefit: If successful, this approach could increase screening uptake and timely treatment, reducing cervical cancer deaths.
How similar studies have gone: Preliminary data from MD Anderson in Mozambique show feasibility and patient preference for self-collection, suggesting potential success in broader rollout.
Where this research is happening
-
Tulane University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Moon, D. Troy — Tulane University of Louisiana
- Study coordinator: Moon, D. Troy
Related research
Other NIH-funded projects on the same topics.
-
Community and digital tools to reduce HPV and cervical cancer burden
A nurse or health team will test a community-based, digital strategy to help girls and young women, especially in rural areas, get HPV vaccination and cervical cancer prevention services.
-
Community and digital tools to reduce HPV and cervical cancer in women with HIV
A community- and digital-technology program aims to help girls and young women, including those with HIV, get more HPV vaccination and cervical cancer prevention services.
-
mSaada: a mobile tool to boost cervical cancer screening in western Kenya
A mobile app helps community health volunteers manage cervical cancer screening tasks and follow-up for women in low-resource areas.
-
Globally useful predictor for cervical cancer treatment response
This project aims to develop a simple predictive signature to personalize treatment for locally advanced cervical cancer using easy tests and imaging.
-
HPV self-collection in HIV care to screen for cervical cancer in Ethiopia
A patient-centered program tests a simple HPV self-collection approach within HIV clinics in Ethiopia to help detect cervical cancer earlier.
-
Hybrid approach to boost cervical cancer screening in Uganda
A tested, community-driven program helps Ugandan women encourage their peers to get free VIA cervical cancer screening.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.